When Is Depression a Terminal Illness? Deliberative Suicide in Chronic Mental Illness – by Constance E. George, MD, MA – Jun 2016
In this discussion about the validity of suicide in patients with untreatable depression, it struck me that it could just as well apply to patients with chronic pain, untreatable without opioids, when opioids are no longer allowed.
This article concludes:
“So, an important lesson … has to do with understanding that mental illness can be a terminal illness and that the concept of hope has therapeutic limitations.” Continue reading
Pain and gastrointestinal dysfunction are significant associations with psychiatric disorders in patients with Ehlers-Danlos syndrome and hypermobility spectrum disorders – PubMed – NCBI – Mar 2019
Unfortunately, we don’t have access to the full article, but even the abstract shows that EDS is a systemic dysfunction. Symptoms show up in various bodily systems, leading to both physical and mental health problems.
In this retrospective study, we investigate the frequency and types of psychiatric disorders and their relationship to systemic manifestations in a cohort of 391 Ehlers-Danlos syndromes (EDS) and hypermobility spectrum disorder (HSD) patients based on the current 2017 International Classification of EDS diagnostic criteria. Continue reading
Suicide prevention experts: What you say (and don’t say) could save a person’s life – Alia E. Dastagir, USA TODAY – Sept. 2018
On average, there are more than 128 suicides per day in the United States, attempted by people with and without known mental health conditions. USA TODAY.
It’s crazy that even the most biased and highest estimates (by the conflation of any and all drugs) of overdose deaths are only about half the number of suicides, but no big money groups or politicians are advocating for “suicide prevention”.
So suicide deaths are almost twice as common as “opioid overdose” deaths, yet very little is being done to address this much more serious issue. Continue reading
Opiates as antidepressants. – PubMed – NCBI – Curr Pharm Des. 2009
Antidepressants are frequently touted as useful for chronic pain and it’s not clear if that is because they relieve pain-induced depression and thus make the pain less bothersome or if they specifically relieve the pain.
Here are two research studies showing that opioids may directly relieve depression, not just pain, further complicating the two-way relationships between pain and depression and also between pain-relievers and “depression-relievers”.
The pathophysiology of mood disorders involves several genetic and social predisposing factors, as well as a dysregulated response to a chronic stressor, i.e. chronic pain. Continue reading
Cooperative opioid and serotonergic mechanisms generate superior antidepressant-like effects in a mice model of depression | International Journal of Neuropsychopharmacology | Oxford Academic – free full text – September 2009
Perhaps this is another way that opioids help us deal with chronic pain. I know I’m more depressed when I’m having serious pain because it reminds me of all I’ve had to give up because of it. My future looks pretty grim when viewed through a thick haze of pain.
On days my pain isn’t so bad or I’ve managed to get it under control with opioid medication, I feel more hopeful about the future as I busy myself with all kinds of little tasks I cannot do when my pain is bad.
The opioid system has been implicated in the aetiology of depression, and some preclinical and clinical data suggest that opioids possess a genuine antidepressant-like effect.
Mindfulness research’s huge problem with uninformative control groups – by James C Coyne – June 2016
Are enthusiasts protecting cherished beliefs about the power of mindfulness from disconfirmation?
Do any advantages of mindfulness training disappear in a fairly matched cage fight with a treatment of comparable frequency and intensity?
Finally, a more thorough look at the research indicates that mindfulness is more a placebo response than a treatment. It makes no sense that it’s recommended by medical experts in the place of effective medication. Continue reading
Fast-Acting Depression Drug, Newly Approved, Could Help Millions – By Benedict Carey – Mar 2019
This is wonderful news because it’s from a different drug class than what’s been available.
This new approach brings fresh hope for those of us who have been hanging on, gritting our teeth, and tolerating our treatment-resistant depression because we can’t get sufficient relief from the current medications.
A nasal spray version of the drug ketamine has shown promise as an antidepressant, even if its properties still aren’t well understood. Continue reading
With what we know about addiction these days, it makes no sense to split the “substance dependence” diagnoses into groups by the specific drug. Addiction happens when the brain habituates to a malfunction of satisfying cravings despite increasing harms.
It’s the users that become addicted and have a problem, not the substance!
Wikipedia information on DSM-5
The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) is the 2013 update to the Diagnostic and Statistical Manual of Mental Disorders, the taxonomic and diagnostic tool published by the American Psychiatric Association (APA). Continue reading
Depression treatment needs overhaul – by Tess Redgrave, University of Auckland
This is an interesting article that proposes 12 categories of depression, with different symptoms and requiring different treatment.
The way depression is diagnosed and treated needs a major overhaul, say authors of a new review article in the scientific journal Brain, Behavior, and Immunity.
This is because current treatment of depression is ineffective and lacks a plausible, coherent theoretical basis, they claim.
A new theory for depression and its treatment is proposed in the article “Depression subtyping based on evolutionary psychiatry: Proximate mechanisms and ultimate functions,” Continue reading
Unwanted Events and Side Effects in Cognitive Behavior Therapy – Cognitive Therapy and Research – June 2018
Side effects (SEs)are negative reactions to an appropriately delivered treatment, which must be discriminated from unwanted events (UEs) or consequences of inadequate treatment.
One hundred CBT therapists were interviewed for UEs and SEs in one of their current outpatients.
Therapists reported 372 UEs in 98 patients and SEs in 43 patients. Continue reading